

Zinnia P Parra-Guillen

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7900584/publications.pdf>

Version: 2024-02-01

34
papers

452
citations

687363

13
h-index

752698

20
g-index

34
all docs

34
docs citations

34
times ranked

829
citing authors

#	ARTICLE	IF	CITATIONS
1	Gene Therapy: A Pharmacokinetic/Pharmacodynamic Modelling Overview. <i>Pharmaceutical Research</i> , 2010, 27, 1487-1497.	3.5	40
2	Review on modeling anti-antibody responses to monoclonal antibodies. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 2014, 41, 523-536.	1.8	39
3	Pharmacometrics Markup Language (PharmML): Opening New Perspectives for Model Exchange in Drug Development. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2015, 4, 316-319.	2.5	37
4	Pharmacokinetics and Pharmacokinetic-Pharmacodynamic Relationships of Monoclonal Antibodies in Children. <i>Clinical Pharmacokinetics</i> , 2015, 54, 35-80.	3.5	34
5	Semimechanistic Bone Marrow Exhaustion Pharmacokinetic/Pharmacodynamic Model for Chemotherapy-Induced Cumulative Neutropenia. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2017, 362, 347-358.	2.5	27
6	Mathematical Model Approach to Describe Tumour Response in Mice After Vaccine Administration and its Applicability to Immune-Stimulatory Cytokine-Based Strategies. <i>AAPS Journal</i> , 2013, 15, 797-807.	4.4	24
7	Utilising the EGFR interactome to identify mechanisms of drug resistance in non-small cell lung cancer – Proof of concept towards a systems pharmacology approach. <i>European Journal of Pharmaceutical Sciences</i> , 2016, 94, 20-32.	4.0	22
8	Exploiting Pharmacokinetic Models of Tamoxifen and Endoxifen to Identify Factors Causing Subtherapeutic Concentrations in Breast Cancer Patients. <i>Clinical Pharmacokinetics</i> , 2018, 57, 229-242.	3.5	21
9	Modeling Tumor Response after Combined Administration of Different Immune-Stimulatory Agents. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2013, 346, 432-442.	2.5	19
10	Pharmacokinetic/Pharmacodynamic Evaluation of Hydrocortisone Therapy in Pediatric Patients with Congenital Adrenal Hyperplasia. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, e1729-e1740.	3.6	18
11	Role of Cytochrome P450 3A4 and 1A2 Phenotyping in Patients with Advanced Non-small Cell Lung Cancer Receiving Erlotinib Treatment. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2017, 121, 309-315.	2.5	17
12	The Fusion Protein of IFN- γ and Apolipoprotein A-I Crosses the Blood-Brain Barrier by a Saturable Transport Mechanism. <i>Journal of Immunology</i> , 2012, 188, 3988-3992.	0.8	16
13	Model Description Language (MDL): A Standard for Modeling and Simulation. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2017, 6, 647-650.	2.5	15
14	Predicting Cortisol Exposure from Paediatric Hydrocortisone Formulation Using a Semi-Mechanistic Pharmacokinetic Model Established in Healthy Adults. <i>Clinical Pharmacokinetics</i> , 2018, 57, 515-527.	3.5	15
15	Machine Learning Analysis of Individual Tumor Lesions in Four Metastatic Colorectal Cancer Clinical Studies: Linking Tumor Heterogeneity to Overall Survival. <i>AAPS Journal</i> , 2020, 22, 58.	4.4	14
16	Mechanistic Modeling of a Novel Oncolytic Virus, V937, to Describe Viral Kinetic and Dynamic Processes Following Intratumoral and Intravenous Administration. <i>Frontiers in Pharmacology</i> , 2021, 12, 705443.	3.5	11
17	Paediatric population pharmacokinetic modelling to assess hydrocortisone replacement dosing regimens in young children. <i>European Journal of Endocrinology</i> , 2020, 183, 357-368.	3.7	10
18	Systematic Modeling and Design Evaluation of Unperturbed Tumor Dynamics in Xenografts. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2018, 366, 96-104.	2.5	9

#	ARTICLE	IF	CITATIONS
19	The circadian rhythm of corticosteroid-binding globulin has little impact on cortisol exposure after hydrocortisone dosing. <i>Clinical Endocrinology</i> , 2019, 91, 33-40.	2.4	9
20	A Quantitative Systems Pharmacology Model for the Key Interleukins Involved in Crohn's Disease. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2020, 372, 299-307.	2.5	9
21	Disease pharmacokinetic-pharmacodynamic modelling in acute intermittent porphyria to support the development of mRNA-based therapies. <i>British Journal of Pharmacology</i> , 2020, 177, 3168-3182.	5.4	8
22	Relevance of primary lesion location, tumour heterogeneity and genetic mutation demonstrated through tumour growth inhibition and overall survival modelling in metastatic colorectal cancer. <i>British Journal of Clinical Pharmacology</i> , 2022, 88, 166-177.	2.4	7
23	The Long Neglected Player: Modeling Tumor Uptake to Guide Optimal Dosing. <i>Clinical Cancer Research</i> , 2018, 24, 3236-3238.	7.0	6
24	Model-Informed Dose Selection for Xentuzumab, a Dual Insulin-Like Growth Factor-1/II Neutralizing Antibody. <i>Clinical Pharmacology and Therapeutics</i> , 2020, 107, 597-606.	4.7	6
25	Population Pharmacokinetic Modelling of Irosustat in Postmenopausal Women with Oestrogen-Receptor Positive Breast Cancer Incorporating Non-Linear Red Blood Cell Uptake. <i>Pharmaceutical Research</i> , 2015, 32, 1493-1504.	3.5	5
26	Target-Mediated Disposition Model Describing the Dynamics of IL12 and IFN γ after Administration of a Mifepristone-Inducible Adenoviral Vector for IL-12 Expression in Mice. <i>AAPS Journal</i> , 2013, 15, 183-194.	4.4	4
27	Computational disease model of phenobarbital-induced acute attacks in an acute intermittent porphyria mouse model. <i>Molecular Genetics and Metabolism</i> , 2019, 128, 367-375.	1.1	2
28	Kinetic and Dynamic Computational Model-Based Characterization of New Proteins in Mice: Application to Interferon Alpha Linked to Apolipoprotein A-I. <i>PLoS ONE</i> , 2012, 7, e42100.	2.5	2
29	Semi-Mechanistic Model for the Antitumor Response of a Combination Cocktail of Immuno-Modulators in Non-Inflamed (Cold) Tumors. <i>Cancers</i> , 2021, 13, 5049.	3.7	2
30	Immune network for viral hepatitis B: Topological representation. <i>European Journal of Pharmaceutical Sciences</i> , 2019, 136, 104939.	4.0	1
31	A quantitative systems pharmacology model for acute viral hepatitis B. <i>Computational and Structural Biotechnology Journal</i> , 2021, 19, 4997-5007.	4.1	1
32	Making use of modeling and simulations: Towards individualized tamoxifen therapy in breast cancer. <i>International Journal of Clinical Pharmacology and Therapeutics</i> , 2017, 55, 690-691.	0.6	1
33	Mechanistic modelling of enzyme restoration effects of new recombinant liver-targeted proteins in acute intermittent porphyria. <i>British Journal of Pharmacology</i> , 2022, , .	5.4	1
34	Response to Hydrocortisone suspension formulations are not necessarily the same in the treatment of children with congenital adrenal hyperplasia. <i>European Journal of Endocrinology</i> , 2020, 183, L29-L30.	3.7	0